Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
announced positive results from the Phase 3 VALOR study, a 52-week placebo-controlled trial evaluating the once-daily oral drug brepocitinib in patients with dermatomyositis/DM. This trial enrolled 241 subjects globally and is noted as the longest and largest interventional DM study ever conducted. The study met its primary endpoint, with the brepocitinib 30 mg dose achieving a week 52 mean Total Improvement Score/TIS of 46.5, compared to 31.2 for placebo. A statistically significant difference in mean TIS between the 30 mg dose and placebo was observed as early as week 4 and was sustained throughout the one-year study. Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints This result marks the first-ever positive outcome for a 52-week placebo-controlled trial and the first positive registrational trial for a targeted therapy in DM. Brepocitinib 30 mg also demonstrated clinically meaningful and statistically significant improvement ove
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]Forbes
- Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ROIV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]Seeking Alpha
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- ROIV's page on the SEC website